Activities per year
Activities
- 4 results
Search results
-
Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1–49% or ≥50%
Izumi, H. (Speaker) & Hiltermann, J. (Contributor)
7-Mar-2025Activity: Talk and presentation › Academic presentation › Academic
-
Interim analysis of a randomized study of 1L BMS-986012 (anti-fucosyl-GM-1) with Chemotherapy and nivolumab in ES-SCLC
Sugawara, S. (Speaker) & Hiltermann, J. (Contributor)
6-Mar-2025Activity: Talk and presentation › Academic presentation › Academic
-
Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%
Hiltermann, J. (Invited speaker)
9-Sept-2024Activity: Talk and presentation › Academic presentation › Academic
File -
Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance After Chemo-Immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study
Lau, S. C. M. (Speaker) & Hiltermann, T. J. N. (Contributor)
9-Sept-2024Activity: Talk and presentation › Academic presentation › Academic